Event Details

ASH 2017 Presentation Details:

December 11, 2017 at 7:00 AM EST

Presentation Title:In Vitro and Preclinical In Vivo Evidence Support MDMX/MDM2 as Common Vulnerabilities Across TP53-Wild-Type T-Cell Lymphomas That Are Targetable with the Alpha-Helical P53 Stapled Peptide ALRN-6924”
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Targeted therapies for Non-Hodgkin's Lymphomas
Session Date: Monday, December 11, 2017
Session Time: 7:00 a.m. - 8:30 a.m. EST
Presentation Time: 7:00 a.m. EST

Presentation Title“Dual Inhibition of MDMX and MDM2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia”
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Novel Therapeutics and Mechanisms of Resistance in Myeloid Disease
Session Date: Monday, December 11, 2017
Session Time: 4:30 p.m. – 6:00 p.m. EST
Presentation Time: 5:00 p.m. EST